{"id":924764,"date":"2026-01-07T08:11:10","date_gmt":"2026-01-07T13:11:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/"},"modified":"2026-01-07T08:11:10","modified_gmt":"2026-01-07T13:11:10","slug":"johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/","title":{"rendered":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration"},"content":{"rendered":"

<\/p>\n

Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration<\/b><\/p>\n

Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification<\/i><\/p>\n

Second IDE approved for U.S. clinical trial for OTTAVA in inguinal hernia procedures<\/i><\/p>\n

NEW BRUNSWICK, N.J.–(BUSINESS WIRE<\/a>)–
\nJohnson & Johnson today announced that the company has submitted the OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.<\/p>\n

\n\u201cWe have taken learnings from Johnson & Johnson\u2019s 140 years in surgery, our decades of leadership in minimally invasive surgery, and the experiences robotic surgeons and hospitals have had over the past 20 years to design a soft tissue robotic system built for the future of surgery,\u201d said Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson. \u201cI am proud of the design decisions and major scientific efforts that have gone into the system to support surgeons and successfully complete our first clinical trial, and I look forward to reaching the next milestone on our path to commercialization.\u201d<\/p>\n

Data from first clinical trial supporting submission
\n
<\/b>First cases in the OTTAVA IDE study were completed in early 2025 at Memorial Hermann-Texas Medical Center by Dr. Erik Wilson*, Chief of Minimally Invasive and Elective General Surgery UT Health Houston and the lead investigator for the clinical study.<\/p>\n

\nOTTAVA\u2019s unique unified architecture, surgical instrumentation powered by Ethicon expertise, and future connection to the Polyphonic\u2122 digital ecosystem<\/a> are designed to address the unmet needs of surgeons and their teams. The Company filed data from the completed clinical trial with the aim of showcasing safety and effectiveness and supporting the system\u2019s ability to perform a variety of procedures. Given OTTAVA\u2019s novel architecture and differentiated technological capabilities, the company filed a De Novo classification request and is targeting an indication covering multiple procedures in general surgery within the upper abdomen, such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair.<\/p>\n

\n\u201cThe IDE study builds on a significant body of preclinical evidence we have generated demonstrating the impact of the OTTAVA system and provides critical clinical evidence on the system performance,\u201d said Peter Schulam, M.D., Ph.D., Chief Scientific Officer, MedTech, Johnson & Johnson. \u201cSurgeon investigators across several hospitals led this important study to further clinical evidence in support of minimally invasive, robotic-assisted surgery for the benefit of clinical teams, hospitals, and patients.\u201d<\/p>\n

Second clinical trial approved in hernia repair
\n
<\/b>OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. In late 2025, Johnson & Johnson received IDE approval to begin a U.S. clinical trial for OTTAVA in inguinal hernia procedures, one of the most common surgeries in the U.S.1<\/sup><\/p>\n

\nThe OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market. For more information, visit: http:\/\/thenext.jnjmedtech.com\/surgical-robotics<\/a>.<\/p>\n

About Surgical Solutions from Johnson & Johnson MedTech
\n
<\/b>Across Johnson & Johnson, we are tackling the world\u2019s most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound clossure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what\u2019s next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit https:\/\/thenext.jnjmedtech.com<\/a>.<\/p>\n

About Johnson & Johnson
\n
<\/b>At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.<\/p>\n

\nLearn more about our MedTech sector\u2019s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https:\/\/thenext.jnjmedtech.com<\/a>. Follow us at @JNJMedTech and on LinkedIn.<\/p>\n

Cautions Concerning Forward-Looking Statements
\n
<\/b>The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson\u2019s most recent Annual Report on Form 10-K, including in the sections captioned \u201cCautionary Note Regarding Forward-Looking Statements\u201d and \u201cItem 1A. Risk Factors,\u201d and in Johnson & Johnson\u2019s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov<\/a>, www.jnj.com<\/a>, www.investor.jnj.com<\/a> or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.<\/p>\n

Footnotes
\n
<\/b>*Dr. Wilson is a paid consultant for Johnson & Johnson MedTech.<\/p>\n

1<\/sup> IQVIA Hospital Procedure Data Set, 2023 actuals<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260107730308\/en\/<\/a><\/span><\/p>\n

\nMedia contact:
\n
Lindsey Diaz-MacInnis
\n
LDiazMac@ITS.JNJ.com<\/a><\/p>\n

KEYWORDS:<\/b> New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health FDA Surgery Health Insurance Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification Second IDE approved for U.S. clinical trial for OTTAVA in inguinal hernia procedures NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– Johnson & Johnson today announced that the company has submitted the OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. \u201cWe have taken learnings from Johnson & Johnson\u2019s 140 years in surgery, … <\/p>\n

Continue reading “Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924764","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nJohnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification Second IDE approved for U.S. clinical trial for OTTAVA in inguinal hernia procedures NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– Johnson & Johnson today announced that the company has submitted the OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. \u201cWe have taken learnings from Johnson & Johnson\u2019s 140 years in surgery, … Continue reading "Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T13:11:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration\",\"datePublished\":\"2026-01-07T13:11:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/\"},\"wordCount\":1087,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/\",\"name\":\"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-01-07T13:11:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk","og_description":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification Second IDE approved for U.S. clinical trial for OTTAVA in inguinal hernia procedures NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– Johnson & Johnson today announced that the company has submitted the OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. \u201cWe have taken learnings from Johnson & Johnson\u2019s 140 years in surgery, … Continue reading \"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T13:11:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration","datePublished":"2026-01-07T13:11:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/"},"wordCount":1087,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/","name":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-01-07T13:11:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260107730308r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson Submits OTTAVA\u2122 Robotic Surgical System to the U.S. Food and Drug Administration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924764"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924764\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}